Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 7/20 | 0.46 |
| ▸ | CA2 | P00918 | 7/20 | 0.46 |
| ▸ | CA12 | O43570 | 6/20 | 0.46 |
| ▸ | CA9 | Q16790 | 6/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | STK17B | O94768 | 1/20 | 0.39 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8892710 | 1.00 | MEN1 (0.55) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL3462865 | 0.95 | TDP1 (0.57) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL3462867 | 0.95 | TDP1 (0.57) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL8411840 | 0.94 | TDP1 (0.59) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL7438984 | 0.94 | TDP1 (0.59) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL14312158 | 0.90 | MEN1 (0.50) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL16858665 | 0.87 | EPHX2 (0.49) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL28497839 | 0.87 | EPHX2 (0.49) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL13504656 | 0.87 | TDP1 (0.54) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL28922732 | 0.86 | TDP1 (0.53) | MEN1GAAKMT2ATDP1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2111391-B9 | NEW UNSATURATED FATTY AMINO-ACID DERIVATIVES AND USE THEREOF IN DERMAL COSMETOLOGY | FABRE PIERRE DERMO COSMETIQUE (FR) | 2013-05-29 | — | — | EP | claimed |
| EP-2111391-B1 | NEW UNSATURATED FATTY AMINO-ACID DERIVATIVES AND USE THEREOF IN DERMAL COSMETOLOGY | FABRE PIERRE DERMO COSMETIQUE (FR) | 2012-10-31 | — | — | EP | claimed |
| EP-2111391-B9 | NEW UNSATURATED FATTY AMINO-ACID DERIVATIVES AND USE THEREOF IN DERMAL COSMETOLOGY | FABRE PIERRE DERMO COSMETIQUE (FR) | 2013-05-29 | — | — | EP | disclosed |
| EP-2111391-B1 | NEW UNSATURATED FATTY AMINO-ACID DERIVATIVES AND USE THEREOF IN DERMAL COSMETOLOGY | FABRE PIERRE DERMO COSMETIQUE (FR) | 2012-10-31 | — | — | EP | disclosed |
| EP-0773950-B1 | LINKED PEPTIDE NUCLEIC ACIDS | ISIS PHARMACEUTICALS INC (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20030105286-A1 | Linked peptide nucleic acids | EGHOLM MICHAEL (US) | 2003-06-05 | — | — | US | disclosed |
| US-6451968-B1 | HOOGSTEEN TYPE BASE PAIRING IN TRIPLEX MOTIF; DIAGNOSIS; HEAT RESISTANCE; DETECTION OF POINT MUTATIONS, RESTRICTION ENZYME SITES, AND TRANSCRIPTION INHIBITION | ISIS PHARMACEUTICALS, INC. | 2002-09-17 | — | — | US | disclosed |
| US-6441130-B1 | FORM TRIPLE STRANDED STRUCTURES WITH NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. | 2002-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105286-A1 | Linked peptide nucleic acids | RNGTT, NT5C3B, DPYD | MEN1 4398/4885GAA 2330/4885KMT2A 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.